Effect of South Beach Diet (SBD™) Using SBD™ Products Compared to the American Diabetic Association (ADA) Diabetes Meal Plan on Body Weight and Satiety in Diabetic Women
This study has been completed.
Sponsor:
Mondelēz International, Inc.
Collaborator:
KGK Synergize Inc.
Information provided by:
Mondelēz International, Inc.
ClinicalTrials.gov Identifier:
NCT00931034
First received: June 29, 2009
Last updated: June 30, 2009
Last verified: June 2009
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to examine the effectiveness of the South Beach Diet and products compared to the American Diabetic Association Diabetes Meal Plan.
| Condition | Intervention |
|---|---|
|
Type 2 Diabetes Mellitus |
Behavioral: South Beach Diet with South Beach Diet Products Behavioral: American Diabetes Association Diabetes Meal Plan |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | The Effect of South Beach Diet™ Using South Beach Diet™ Products Compared to the American Diabetic Association Diabetes Meal Plan on Body Weight and Satiety in Overweight Diabetic Women |
Resource links provided by NLM:
Further study details as provided by Mondelēz International, Inc.:
Primary Outcome Measures:
- Change in body weight from baseline to week 24 [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Assess the satiety response to the individual diets [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
- Analyze circumference measurements & body composition; blood glucose, HbA1c, insulin, lipid profile, blood pressure & questionnaire responses on food cravings and quality of life [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
| Enrollment: | 120 |
| Study Start Date: | March 2007 |
| Study Completion Date: | July 2008 |
| Primary Completion Date: | April 2008 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: South Beach Diet with SBD Products | Behavioral: South Beach Diet with South Beach Diet Products |
| Active Comparator: ADA Diabetes meal plan | Behavioral: American Diabetes Association Diabetes Meal Plan |
Eligibility| Ages Eligible for Study: | 18 Years to 55 Years |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Female age 18 to 55 years
- Females of childbearing potential must agree to use a medically approved method of birth control and have a negative urine pregnancy test result
- Healthy as determined by laboratory results and medical history
- Waist circumference > 87 cm
- Stable weight defined as < 4.5 kg gained or lost in past year
- Agreement to maintain current level of physical activity throughout the study
- Diagnosed with Type II diabetes mellitus with fasting blood glucose 100 - 250 mg/dl (5.6 - 13.9 mmol/L)
- Ability to comprehend and complete the questionnaires and forms
- Agreement to comply with study procedures, test article consumption, and has access to a microwave oven
- Voluntary, written, informed consent to participate in the study
Exclusion Criteria:
- Pregnant, breastfeeding, or planning to become pregnant during the course of the trial
Use of prescription or over the counter products known to effect weight including but not limited to the following:
- megestrol acetate;
- somatropin;
- sibutramine;
- orlistat;
- paroxetine;
- dextroamphetamine;
- methylphenidate;
- atomoxetine;
- quetiapine;
- olanzepine;
- risperidone, within 4 weeks of randomization and during the trial
- Unstable medication for diabetes mellitus (Dosage must be stable for 90 days prior to randomization), use of insulin is exclusionary
- Alcohol use > 2 standard alcoholic drinks per day
Significant cardiac history defined as a history of:
- myocardial infarction (MI);
- coronary angioplasty or bypass graft(s);
- valvular disease or repair;
- unstable angina pectoris;
- transient ischemic attack (TIA);
- cerebrovascular accidents (CVA);
- congestive heart failure; or
- coronary artery disease (CAD)
- History of or current diagnosis of any cancer (except for successfully treated basal cell carcinoma) diagnosed less than 5 years prior to screening. Subjects with cancer in full remission for more than 5 years are acceptable.
- Uncontrolled hypertension defined as untreated systolic blood pressure > 160 mmHg and/or diastolic blood pressure > 100 mmHg
- Unstable renal and/or liver disease
- History of alcohol or drug abuse within the past year
- Unstable psychiatric disorder requiring hospitalization within the past 6 months
- Immunocompromised individuals such as subjects that have undergone organ transplantation or subjects diagnosed with human immunodeficiency virus (HIV)
- History of hemoglobinopathies such as sickle cell anemia or thalassemia, sideroblastic anemia
- Participation in another clinical research trial within 30 days prior to randomization and during the trial
- Significant abnormal liver function as defined as AST and/or ALT > 2 x ULN, and/or bilirubin > 2 x ULN
- Serum creatinine > 125 umol/L
- Anemia of any etiology defined as hemoglobin < 110 g/L
- Uncontrolled and/or untreated thyroid disorder
- Unstable medications (Dosage must be stable for 90 days prior to randomization)
- History of food allergies or sensitivities, including lactose intolerance
- Vegetarians
- Cognitively impaired and/or unable to give informed consent
- Any other condition which in the Investigator's opinion may adversely affect the subject's ability to complete the study or its measures or which may pose significant risk to the subject
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00931034
Locations
| United States, California | |
| Medicus Research | |
| Northridge, California, United States, 91325 | |
| United States, Florida | |
| SIBR Research | |
| Bradenton, Florida, United States, 34205 | |
| Miami Research Associates | |
| Miami, Florida, United States, 33143 | |
| United States, Nevada | |
| Nevada Alliance Against Diabetes | |
| Las Vegas, Nevada, United States, 89101 | |
| United States, New York | |
| Rochester Clinical Research Inc | |
| Rochester, New York, United States, 14609 | |
| United States, Virginia | |
| Chase Wellness & Research Center | |
| Virginia Beach, Virginia, United States, 23455 | |
Sponsors and Collaborators
Mondelēz International, Inc.
KGK Synergize Inc.
Investigators
| Study Director: | David Crowley, MD | KGK Synergize Inc. |
More Information
No publications provided
| Responsible Party: | Richard Black, PhD/VP, Nutrition, Kraft Foods |
| ClinicalTrials.gov Identifier: | NCT00931034 History of Changes |
| Other Study ID Numbers: | 07SWHK |
| Study First Received: | June 29, 2009 |
| Last Updated: | June 30, 2009 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Mondelēz International, Inc.:
|
South Beach Diet™ overweight obesity |
satiety weight loss diabetes |
Additional relevant MeSH terms:
|
Body Weight Diabetes Mellitus Diabetes Mellitus, Type 2 Signs and Symptoms |
Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases |
ClinicalTrials.gov processed this record on May 23, 2013